






Ex Vivo Mitochondrial Respiration Parallels Biochemical Response to Ibrutinib in CLL Cells

Subir Roy Chowdhury¹, Cheryl Peltier¹, Sen Hou², Amandeep Singh¹, James B. Johnston¹, Spencer B. Gibson^{1,2,3}, Aaron J. Marshall^{1,2,3,4} and Versha Banerji^{1,3,4,*}

Decreased mitochondrial respiration in chronic lymphocytic leukemia (CLL) cells from patients on ibrutinib treatment compared to pre-treatment

Figure 1. Ibrutinib has similar effects on mitochondrial respiration profiles in CLL patients independent of dose. The effect of ibrutinib treatment (IB) on ROUTINE respiration (A), ET capacity (B), and E-R reserve capacity (C) in primary CLL cells from patients pre-treatment and on ibrutinib treatment with low (blue) or standard (grey) dose. $N = 14$ for low dose and $N = 5$ for standard dose of ibrutinib. Values are mean \pm S.D. $x = 10 \cdot 10^6$ cells, **** $p < 0.0001$.



Patients with CLL progression while on ibrutinib treatment show increased mitochondrial respiration




Figure 2. Patients progressed while on ibrutinib treatment have increased mitochondrial respiration profiles. ROUTINE respiration (A), ET capacity (B), and E-R reserve capacity (C) are summarized in freshly isolated CLL cells from ibrutinib-sensitive (green) and patients who have progressed on ibrutinib (red). Values are mean \pm S.D., ibrutinib-sensitive, $N = 19$, and ibrutinib-progressed, $N = 7$. $x = 10 \cdot 10^6$ cells, ** $p < 0.005$, *** $p < 0.0005$

Mitochondrial respiration of CLL cells is similarly altered regardless of ibrutinib dose in responding patients, supporting the rationale for dose reductions based on the use of a novel biomarker and mitochondrial respiration. The increase of mitochondrial respiration in patients that have progressed on therapy further supports mitochondrial respiration of CLL cells as a biomarker of active disease. Mitochondrial respiration can serve as a preclinical tool that can help identify novel compounds in the future, which can be used in parallel with standard available tools.

Reference: Chowdhury SR, Peltier C, Hou S, Singh A, Johnston JB, Gibson SB, Marshall A, Banerji V (2021) Ex vivo mitochondrial respiration parallels biochemical response to ibrutinib in CLL cells. *Cancers (Basel)* 13:E354.

Text slightly modified based on the recommendations of the COST Action MitoEAGLE CA15203. doi:10.26124/hec:2020-0001.v1

**O2k-brief communicated by T Komlodi and L Tindle-Solomon
 Oroboros Instruments**